Increased T cell proliferative responses to islet antigens identify clinical responders to anti-CD20 monoclonal antibody (rituximab) therapy in Type 1 diabetes

Type 1 diabetes mellitus (T1DM) is believed to be due to the autoimmune destruction of β-cells by T lymphocytes, but a single course of rituximab, a monoclonal anti-CD20 B lymphocyte antibody can attenuate C-peptide loss over the first year of disease. The effects of B cell depletion on disease asso...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Herold, Kevan C., Pescovitz, Mark D, McGee, Paula, Krause-Steinrauf, Heidi, Spain, Lisa M., Bourcier, Kasia, Asare, Adam, Liu, Zhugong, Lachin, John M, Dosch, H Michael
Médium: Artigo
Jazyk:Inglês
Vydáno: 2011
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3150302/
https://ncbi.nlm.nih.gov/pubmed/21775681
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4049/jimmunol.1100539
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky